 |
|
|
| |
Predictors of Response to Elbasvir/Grazoprevir Among HCV Genotype 1
(GT1)-Infected Patients: Integrated Analysis of Phase 2-3 Trials -2
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Zeuzem S1; Rockstroh J2; Kwo P3; Roth D4; Lawitz E5; Sulkowski M6;
Forns X7; Wahl J8; Robertson M8; Nguyen B-Y8; Barr E8; Howe A8*; Miller M8;
Hwang P8; Chen E8; Koury K8
1Goethe University Hospital, Frankfurt, Germany; 2Bonn University Hospital, Bonn, Germany; 3Indiana University School of Medicine, Indianapolis, IN, USA; 4University of Miami Miller School of Medicine, Miami, FL, USA; 5The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 6Johns Hopkins University School of Medicine, Baltimore, MD, USA; 7Liver Unit, Hospital Clinic, IDIBAPS and CIBEREHD, Barcelona, Spain; 8Merck & Co., Inc., Kenilworth, NJ, USA. *Former employee of Merck & Co., Inc.
|
| |
|
|
|
|
|
